Skip to Content

Genenta has been Awarded to be the First Prize at China-Italy Best Start Up Showcase & Entrepreneurship Competition 2018/2019 (BSSEC)

Oct 14, 2019
ROME (Italy) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), today announced that won the first prize at the BSSEC, China-Italy Best Start Up Showcase and Entrepreneurship Competition 2018/2019. The Chinese venture capital firms, Esco Ventures and Guoqian Venture Capital Investment (Suzhou) were part or the jury that chose between 16 different start-ups in the life science sector. Stefania Mazzoleni, PhD represented Genenta at the competition. Stefania serves at Genenta as Project Manager.